Xenon Pharmaceuticals (XENE) Income from Continuing Operations (2013 - 2026)
Xenon Pharmaceuticals (XENE) posted quarterly Income from Continuing Operations of 102302000.0 for Q1 2026, down 57.27% year-over-year from 239437183.15 in Q1 2025, and up 10.75% quarter-over-quarter from 114630000.0 in Q4 2025.
Xenon Pharmaceuticals (XENE) Income from Continuing Operations (2013 - 2026) Analysis & Trends
Xenon Pharmaceuticals (XENE) has reported Income from Continuing Operations for 14 consecutive years, with 102302000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Income from Continuing Operations fell 57.27% year-over-year to 102302000.0; the TTM figure through Mar 2026 stood at 392534000.0 (down 56.11% YoY), while the FY2025 annual figure was 355279000.0, down 51.61% from the prior year.
- Income from Continuing Operations improved to 102302000.0 in Q1 2026 per XENE's latest filing, from 114630000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 19670000.0 in Q1 2022 and bottomed at 114630000.0 in Q4 2025.
- Historically, Income from Continuing Operations has averaged 58807117.65 across 5 years, with a median of 48462000.0 in 2023.
- Annual changes were most pronounced in 2022 — Income from Continuing Operations slumped 140.53% — and 2024, when it decreased 14.87%.
- Xenon Pharmaceuticals' Income from Continuing Operations stood at 37439000.0 in 2022, then fell by 19.51% to 44743000.0 in 2023, then tumbled by 46.81% to 65685000.0 in 2024, then slumped by 74.51% to 114630000.0 in 2025, then grew by 10.75% to 102302000.0 in 2026.
- Business Quant data shows XENE's Income from Continuing Operations at 102302000.0 in Q1 2026, 114630000.0 in Q4 2025, and 90896000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,096.02 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Xenon Pharmaceuticals | 6.03 Bn | 6.03 Bn | - | -110.74 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -110.74 Mn |
| Mar 31, 2026 | -102.30 Mn |
| Dec 31, 2025 | -114.63 Mn |
| Sep 30, 2025 | -90.90 Mn |
| Jun 30, 2025 | -84.71 Mn |
| Mar 31, 2025 | -65.05 Mn |
| Dec 31, 2024 | -65.69 Mn |
| Sep 30, 2024 | -62.79 Mn |
| Jun 30, 2024 | -57.92 Mn |
| Mar 31, 2024 | -47.93 Mn |
| Dec 31, 2023 | -44.74 Mn |
| Sep 30, 2023 | -48.46 Mn |
| Jun 30, 2023 | -47.46 Mn |
| Mar 31, 2023 | -41.73 Mn |
| Dec 31, 2022 | -37.44 Mn |
| Sep 30, 2022 | -37.15 Mn |
| Jun 30, 2022 | -31.16 Mn |
| Mar 31, 2022 | -19.67 Mn |
| Dec 31, 2021 | -27.60 Mn |
| Sep 30, 2021 | -15.45 Mn |